SOURCES SOUGHT
B -- Research Support Services for the Impact of Rare Diseases on Patients and Healthcare Systems (IDeaS) Initiative Pilot Program
- Notice Date
- 4/27/2023 2:40:25 PM
- Notice Type
- Sources Sought
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95023Q00264
- Response Due
- 5/26/2023 2:00:00 PM
- Point of Contact
- Mark McNally, Phone: 3018275869
- E-Mail Address
-
mark.mcnally@nih.gov
(mark.mcnally@nih.gov)
- Description
- Description:��This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Purposes and Objectives:� The National Center for Advancing Translational Sciences (NCATS) Division of Rare Diseases Research Innovation (DRDRI) is seeking support services to enable the generation of independent analyses, computational tools, and methodologies to facilitate earlier and more accurate identification of rare disease patients. These services will build on previous IDeaS efforts that detailed the prevalence, clinical course, cost, and utilization impact of patients with rare diseases. This next iteration of the IDeaS pilot initiative intends to use the results of the initial pilot study to inform methods for clinical decision support tools to alert clinicians to possible cases of rare diseases. NCATS DRDRI seeks to identify utilization patterns prior to accurate diagnosis and estimate costs of medical care during the diagnostic odyssey, with the larger goal of using this information to inform the development of approaches to diagnose and identify rare disease patients sooner, while improving overall patient care management. Background: NCATS� mission is to improve health through smarter science that results in better treatments faster for all diseases, rare or common. Within that remit, the NCATS DRDRI�s mission is to advance rare disease research to benefit patients. Currently, there are about 7,000-10,000 known rare diseases that affect people in the United States, yet only a few hundred (less than 5%) have a treatment and even fewer a cure. A rare disease is defined in US law (Orphan Drug Act (ODA) of 1983,1 Rare Diseases Act (RDA) of 2002)2 as a disease or condition that affects fewer than 200,000 people in the United States. Most rare diseases affect far fewer patients than this, with most rare diseases affecting only a few hundreds to thousands of patients. Collectively, however, rare diseases are not rare at all, and in total are estimated to affect as many as 25-30 million patients in the United States, making rare diseases a large public health consideration. Given the large number of different rare diseases, each of which affects only a small number of patients, assessing the true impact of rare diseases on healthcare systems in the United States is challenging. Many patients with rare diseases have difficulty obtaining a timely and accurate diagnosis (referred to as the diagnostic odyssey) and there is a lack of data regarding the likely and relatively large number of patients, who have not yet received a rare disease diagnosis. Additionally, International Classification of Disease (ICD) codes largely do not exist for many rare diseases (>50%), leading to myriad downstream effects including difficulty in identifying rare disease patients within healthcare systems databases, imprecise coding of patients under larger �umbrella� (e.g., developmental delay) or �not elsewhere classified (NEC)� terms, poor tracking within databases, and fiscal invisibility given their fragmentation under 1,000s of different terms. This is particularly problematic for (1) characterizing the clinical course of rare disease patients, (2) quantifying (and alleviating) the cost of medical care for people with rare diseases (by disease and in aggregate), (3) and identifying undiagnosed or misdiagnosed rare disease patients. NCATS DRDRI has performed several preliminary feasibility assessments of medical utilization in an initial set of fourteen representative rare diseases and assessed the impacts (utilization and cost) of rare diseases on healthcare systems by leveraging large health databases and analytics support. This next iteration of the IDeaS (Impact of Rare Diseases on Patients and Healthcare Systems) initiative intends to use the results of the initial pilot study (see link to results in attached Statement of Work) to inform methods for clinical decision support tools to alert clinicians to possible cases of rare diseases. DRDRI envisions this will likely involve utilizing the contractor�s databases (access already obtained at time of contract start date) for the below steps to circumvent the lack of diagnostic codes (ICD-9/10) across most rare diseases: Assessment of further case studies � e.g., the creation of specific rare disease profiling (expanded from the initial set of IDeaS 14 diseases) through case definitions Generating list of common features among the rare disease case studies/profiling � e.g., timing of visits (number, specialty), age, cost/utilization, basket ICD terminology Applying and/or generating computational methodology/algorithm to predict for those features Testing generalizability on different population subsets Disseminating methodology/models�� These steps to gather, quantify, and delineate the data for rare disease patients will not only accumulate much-needed rare disease knowledge and help to identify research gaps but will also advance both common and rare disease research, care, and segmentation associated with precision medicine. NCATS DRDRI seeks to identify utilization patterns prior to accurate diagnosis and estimate costs of medical care during the diagnostic odyssey, with the larger goal of using this information to inform the development of approaches to diagnose and identify rare disease patients sooner, while improving overall patient care management. Project requirements: See attached Statement of Work (SOW). Anticipated period of performance: 12-month base period of performance with a 12-month option period of performance. Anticipated to start in fourth quarter fiscal year 2023. Response Instructions Capability statement /information sought. Companies that believe they possess the capabilities to provide the required services should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately.� Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Capability statements must also include the Company Name, Unique Entity ID from SAM.gov, Physical Address, and Point of Contact Information. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer.� Facsimile responses are NOT accepted. The response must be submitted to Mark McNally at mark.mcnally@nih.gov. The response must be received by 5:00 PM Eastern Daylight Time (EDT) on May 26, 2023. �Disclaimer and Important Notes:� This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in www.sam.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).�
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/0d0f6f128adf478497f380d5e1b2d5f6/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN06665276-F 20230429/230427230112 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |